SL44
Based on 1 Customer Validation
SL44 is an agonist for human caseinolytic protease P (HsClpP), with an EC50 of 1.30 μM. SL44 inhibits the proliferation of LM3 with an IC50 of 3.1 μM. SL44 induces apoptosis in HCC cells, through the degradation of respiratory chain complex subunits. SL44 exhibits antitumor efficacy in mouse models without obvious toxicity (LD50=400 mg/kg). SL44 exhibits good pharmacokinetic characters in rat models.
For research use only. We do not sell to patients.
- Purity : 99.57%
- CAS No.: 3054715-45-3
- Formula: C22H20ClFN4O
- Molecular Weight:410.87
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCCLM3 | IC50 |
0.4 μM
Compound: SL44
|
Antiproliferative activity against human HCCLM3 cells overexpressing HsClpP assessed as inhibition of cell growth (Rvb = 2.5 +/- 0.1 microM)
Antiproliferative activity against human HCCLM3 cells overexpressing HsClpP assessed as inhibition of cell growth (Rvb = 2.5 +/- 0.1 microM)
|
[PMID: 38905539] |
| HCCLM3 | IC50 |
19.1 μM
Compound: SL44
|
Antiproliferative activity against human HCCLM3 cells harboring HsClpP knockdown assessed as inhibition of cell growth (Rvb = 2.5 +/- 0.1 microM)
Antiproliferative activity against human HCCLM3 cells harboring HsClpP knockdown assessed as inhibition of cell growth (Rvb = 2.5 +/- 0.1 microM)
|
[PMID: 38905539] |
| HCCLM3 | IC50 |
3.1 μM
Compound: SL44
|
Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 38905539] |
| HepG2 | IC50 |
0.9 μM
Compound: SL44
|
Antiproliferative activity against human HepG2 cells overexpressing HsClpP assessed as inhibition of cell growth (Rvb = 3.5 +/- 0.1 microM)
Antiproliferative activity against human HepG2 cells overexpressing HsClpP assessed as inhibition of cell growth (Rvb = 3.5 +/- 0.1 microM)
|
[PMID: 38905539] |
| HepG2 | IC50 |
10.1 μM
Compound: SL44
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 38905539] |
| HepG2 | IC50 |
18.5 μM
Compound: SL44
|
Antiproliferative activity against human HepG2 cells harboring HsClpP knockdown assessed as inhibition of cell growth (Rvb = 3.5 +/- 0.1 microM)
Antiproliferative activity against human HepG2 cells harboring HsClpP knockdown assessed as inhibition of cell growth (Rvb = 3.5 +/- 0.1 microM)
|
[PMID: 38905539] |
Chemical Information
-
CAS No. 3054715-45-3
-
Appearance Solid
-
Molecular Weight 410.87
-
Formula C22H20ClFN4O
-
Color White to off-white
-
SMILES
ClC1=C(F)C=CC(CC2=NOC(C3CCN(CC4=CC=CC(C#N)=C4)CC3)=N2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 70 mg/mL (170.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Acute Systemic Toxicity Study
Acute systemic toxicity studies evaluate adverse effects occurring after a single exposure, or repeated exposure within a short acute window, and the main in vivo readouts are mortality, moribund condition, clinical signs, body-weight change, and gross pathological findings; acute oral toxicity methods were developed to replace classical LD50 testing with reduced-animal designs such as fixed-dose procedure, acute toxic class method, and up-and-down procedure. The fixed-dose procedure classifies acute toxicity by administering predefined dose levels and observing evident toxicity rather than using death as the primary endpoint, whereas the acute toxic class method uses sequential groups of three animals per step and the up-and-down procedure doses animals sequentially to estimate an LD50 with fewer animals than conventional LD50 testing.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4339 mL | 12.1693 mL | 24.3386 mL | 60.8465 mL |
| 5 mM | 0.4868 mL | 2.4339 mL | 4.8677 mL | 12.1693 mL | |
| 10 mM | 0.2434 mL | 1.2169 mL | 2.4339 mL | 6.0846 mL | |
| 15 mM | 0.1623 mL | 0.8113 mL | 1.6226 mL | 4.0564 mL | |
| 20 mM | 0.1217 mL | 0.6085 mL | 1.2169 mL | 3.0423 mL | |
| 25 mM | 0.0974 mL | 0.4868 mL | 0.9735 mL | 2.4339 mL | |
| 30 mM | 0.0811 mL | 0.4056 mL | 0.8113 mL | 2.0282 mL | |
| 40 mM | 0.0608 mL | 0.3042 mL | 0.6085 mL | 1.5212 mL | |
| 50 mM | 0.0487 mL | 0.2434 mL | 0.4868 mL | 1.2169 mL | |
| 60 mM | 0.0406 mL | 0.2028 mL | 0.4056 mL | 1.0141 mL | |
| 80 mM | 0.0304 mL | 0.1521 mL | 0.3042 mL | 0.7606 mL | |
| 100 mM | 0.0243 mL | 0.1217 mL | 0.2434 mL | 0.6085 mL |